{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:15:02Z","timestamp":1788520502675,"version":"build-2803163510"},"reference-count":116,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["23-65-10014"],"award-info":[{"award-number":["23-65-10014"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.dsx.2024.102949","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T16:53:25Z","timestamp":1706288005000},"page":"102949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic effects of anti-diabetic drugs on traumatic brain injury"],"prefix":"10.1016","volume":"18","author":[{"given":"Seyed Mehrad","family":"Razavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Najafi","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Niknejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasamin","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abtin","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba Darban","family":"Khales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Shahali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Momtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasily N.","family":"Sukhorukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00001199-200609000-00001","article-title":"The epidemiology and impact of traumatic brain injury: a brief overview","volume":"21","author":"Langlois","year":"2006","journal-title":"J Head Trauma Rehabil"},{"issue":"9233","key":"10.1016\/j.dsx.2024.102949_bib2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(00)02689-1","article-title":"Traumatic brain injury","volume":"356","author":"Ghajar","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00019052-200412000-00011","article-title":"Traumatic brain injury: physiology, mechanisms, and outcome","volume":"17","author":"Nortje","year":"2004","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/AIA.0b013e318078cfe7","article-title":"Traumatic brain injury","volume":"45","author":"Parikh","year":"2007","journal-title":"Int Anesthesiol Clin"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.npep.2003.12.003","article-title":"Neurogenic inflammation is associated with development of edema and functional deficits following traumatic brain injury in rats","volume":"38","author":"Nimmo","year":"2004","journal-title":"Neuropeptides"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pmr.2016.12.001","article-title":"Pathophysiology of traumatic brain injury","volume":"28","author":"Dixon","year":"2017","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.dsx.2024.102949_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113621","article-title":"Protective effects of curcumin against traumatic brain injury","volume":"154","author":"Khayatan","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.dsx.2024.102949_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173349","article-title":"Pleiotropic effects of anti-diabetic drugs: a comprehensive review","volume":"884","author":"Nath","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.dsx.2024.102949_bib9","article-title":"Sulfonylurea and cancer risk among patients with type 2 diabetes: a population-based cohort study","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072030","article-title":"Exploring sodium glucose Co-Transporter-2 (SGLT2) inhibitors for organ protection in COVID-19","volume":"9","author":"Fernandez-Fernandez","year":"2020","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.dsx.2024.102949_bib11","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s00701-015-2512-7","article-title":"Epidemiology of traumatic brain injury in Europe","volume":"157","author":"Peeters","year":"2015","journal-title":"Acta Neurochir"},{"issue":"10","key":"10.1016\/j.dsx.2024.102949_bib12","article-title":"Management and treatment of traumatic brain injuries","volume":"14","author":"Jha","year":"2022","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.dsx.2024.102949_bib13","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1089\/neu.2015.4126","article-title":"Epidemiology of traumatic brain injury in europe: a living systematic review","volume":"38","author":"Brazinova","year":"2021","journal-title":"J Neurotrauma"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000338032","article-title":"Incidence of hospital-admitted severe traumatic brain injury and in-hospital fatality in Norway: a national cohort study","volume":"38","author":"Andelic","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269101","article-title":"Sex differences in outcomes from mild traumatic brain injury eight years post-injury","volume":"17","author":"Starkey","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1139\/bcb-2016-0160","article-title":"Traumatic brain injury: classification, models, and markers","volume":"96","author":"Najem","year":"2018","journal-title":"Biochem Cell Biol"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib17","first-page":"213","article-title":"Traumatic brain injury: an overview of epidemiology, pathophysiology, and medical management","volume":"104","author":"Capizzi","year":"2020","journal-title":"Med Clin"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000120025","article-title":"Incidence of hospital-treated traumatic brain injury in the Oslo population","volume":"30","author":"Andelic","year":"2008","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11102-019-00957-9","article-title":"Traumatic brain injury: neuropathological, neurocognitive and neurobehavioral sequelae","volume":"22","author":"Pavlovic","year":"2019","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib20","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/0963689717714102","article-title":"Traumatic brain injury: current treatment strategies and future endeavors","volume":"26","author":"Galgano","year":"2017","journal-title":"Cell Transplant"},{"issue":"23","key":"10.1016\/j.dsx.2024.102949_bib21","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1089\/neu.2021.0062","article-title":"Epidemiology of chronic effects of traumatic brain injury","volume":"38","author":"Haarbauer-Krupa","year":"2021","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.dsx.2024.102949_bib22","article-title":"Microglial polarization in TBI: signaling pathways and influencing pharmaceuticals","volume":"14","author":"Li","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041892","article-title":"Temporal changes in cell marker expression and cellular infiltration in a controlled cortical impact model in adult male C57BL\/6 mice","volume":"7","author":"Jin","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/glia.22762","article-title":"Redox regulation of NF-\u03baB p50 and M1 polarization in microglia","volume":"63","author":"Taetzsch","year":"2015","journal-title":"Glia"},{"key":"10.1016\/j.dsx.2024.102949_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2016.09.014","article-title":"Role of the JAK\/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases","volume":"189","author":"Yan","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.dsx.2024.102949_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ecoenv.2022.113372","article-title":"JAK2\/STAT3 pathway regulates microglia polarization involved in hippocampal inflammatory damage due to acute paraquat exposure","volume":"234","author":"Fan","year":"2022","journal-title":"Ecotoxicol Environ Saf"},{"key":"10.1016\/j.dsx.2024.102949_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4751349","article-title":"Baicalin ameliorates cognitive impairment and protects microglia from LPS-induced neuroinflammation via the SIRT1\/HMGB1 pathway","volume":"2020","author":"Li","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.dsx.2024.102949_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.565667","article-title":"Wnt pathway: an emerging player in vascular and traumatic mediated brain injuries","volume":"11","author":"Menet","year":"2020","journal-title":"Front Physiol"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12974-020-01751-2","article-title":"Advanced oxidation protein products induce microglia-mediated neuroinflammation via MAPKs-NF-\u03baB signaling pathway and pyroptosis after secondary spinal cord injury","volume":"17","author":"Liu","year":"2020","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.dsx.2024.102949_bib30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2147\/DDDT.S223218","article-title":"MsrA suppresses inflammatory activation of microglia and oxidative stress to prevent demyelination via inhibition of the NOX2-MAPKs\/NF-\u03baB signaling pathway","volume":"14","author":"Fan","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib116","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"Journal of Cellular Physiology"},{"issue":"11","key":"10.1016\/j.dsx.2024.102949_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11882-021-01022-x","article-title":"The role of PPAR-\u03b3 in allergic disease","volume":"21","author":"Stark","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10787-022-01017-8","article-title":"Pathogenesis and management of traumatic brain injury (TBI): role of neuroinflammation and anti-inflammatory drugs","volume":"30","author":"Kalra","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"12","key":"10.1016\/j.dsx.2024.102949_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107723","article-title":"Anti-inflammatory properties of antidiabetic drugs: a \"promised land\" in the COVID-19 era?","volume":"34","author":"Katsiki","year":"2020","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.dsx.2024.102949_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155223","article-title":"Metformin: is it a drug for all reasons and diseases?","volume":"133","author":"Triggle","year":"2022","journal-title":"Metabolism"},{"issue":"11\u201312","key":"10.1016\/j.dsx.2024.102949_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1177\/0885066618793385","article-title":"Review of biguanide (metformin) toxicity","volume":"34","author":"Wang","year":"2019","journal-title":"J Intensive Care Med"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib36","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40618-020-01330-5","article-title":"Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs","volume":"44","author":"Chakravarti","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.dsx.2024.102949_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front Endocrinol"},{"issue":"0","key":"10.1016\/j.dsx.2024.102949_bib38","first-page":"170","article-title":"Metformin - its potential anti-cancer and anti-aging effects","volume":"71","author":"Podhorecka","year":"2017","journal-title":"Postepy Hig Med Dosw"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib39","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00604.2020","article-title":"The intersection of metformin and inflammation","volume":"320","author":"Bharath","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib41","first-page":"658","article-title":"Metformin: current knowledge","volume":"19","author":"Nasri","year":"2014","journal-title":"J Res Med Sci"},{"issue":"Suppl 2","key":"10.1016\/j.dsx.2024.102949_bib42","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11892-013-0378-8","article-title":"The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus","volume":"13","author":"Yau","year":"2013","journal-title":"Curr Diabetes Rep"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib45","doi-asserted-by":"crossref","first-page":"445.e1","DOI":"10.1016\/j.ahj.2006.11.005","article-title":"A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes","volume":"153","author":"Stocker","year":"2007","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330802597821","article-title":"How safe is the use of thiazolidinediones in clinical practice?","volume":"8","author":"Rizos","year":"2009","journal-title":"Expet Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib47","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijem.IJEM_556_17","article-title":"Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus - international task force","volume":"22","author":"Kalra","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib49","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-32-32","article-title":"Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer","volume":"32","author":"Rong","year":"2013","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.dsx.2024.102949_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8457010","article-title":"Glibenclamide alleviates LPS-induced acute lung injury through NLRP3 inflammasome signaling pathway","volume":"2022","author":"Yang","year":"2022","journal-title":"Mediat Inflamm"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib51","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/13813455.2020.1789170","article-title":"Glibenclamide as a neuroprotective antidementia drug","volume":"128","author":"Zubov","year":"2022","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.dsx.2024.102949_bib52","series-title":"Second generation. LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib53","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1573399813666170816142351","article-title":"Benefits of SGLT2 inhibitors beyond glycemic control - a focus on metabolic, cardiovascular and renal outcomes","volume":"14","author":"Minze","year":"2018","journal-title":"Curr Diabetes Rev"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib55","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib56","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2174\/1871530319666191014110414","article-title":"A review on the effects of new anti-diabetic drugs on platelet function","volume":"20","author":"Yaribeygi","year":"2020","journal-title":"Endocr, Metab Immune Disord: Drug Targets"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcp.26851","article-title":"Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways","volume":"234","author":"Yaribeygi","year":"2018","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib58","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib59","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"19","key":"10.1016\/j.dsx.2024.102949_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib61","first-page":"45","article-title":"Risks vs benefits for SGLT2 inhibitor medications","volume":"35","author":"Pittampalli","year":"2018","journal-title":"Fed Pract"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib62","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12325-008-0076-1","article-title":"DPP4 inhibitors: a new approach in diabetes treatment","volume":"25","author":"Doupis","year":"2008","journal-title":"Adv Ther"},{"key":"10.1016\/j.dsx.2024.102949_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117152","article-title":"Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes","volume":"241","author":"Yaribeygi","year":"2020","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.dsx.2024.102949_bib64","first-page":"509","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes","volume":"35","author":"Pathak","year":"2010","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00005-020-00602-5","article-title":"DPP4 inhibitors and COVID-19-holy grail or another dead end?","volume":"69","author":"Krejner-Bienias","year":"2021","journal-title":"Arch Immunol Ther Exp"},{"issue":"9","key":"10.1016\/j.dsx.2024.102949_bib66","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib67","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001469","article-title":"Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice","volume":"4","author":"Akita","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib68","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5114\/aoms.2013.34991","article-title":"The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus","volume":"9","author":"Guardado-Mendoza","year":"2013","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.dsx.2024.102949_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.13054","article-title":"Bonus effects of anti-diabetic drugs: possible beneficial effects on endothelial dysfunction, vascular inflammation and atherosclerosis","volume":"123","author":"Pereira","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.dsx.2024.102949_bib70","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2165\/00003495-200161110-00008","article-title":"Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus","volume":"61","author":"Culy","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.dsx.2024.102949_bib71","series-title":"LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12979-022-00264-1","article-title":"Rapamycin, Acarbose and 17\u03b1-estradiol share common mechanisms regulating the MAPK pathways involved in intracellular signaling and inflammation","volume":"19","author":"Wink","year":"2022","journal-title":"Immun Ageing"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib73","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.gendis.2019.05.002","article-title":"Pioglitazone ameliorates neuronal damage after traumatic brain injury via the PPAR\u03b3\/NF-\u03baB\/IL-6 signaling pathway","volume":"7","author":"Deng","year":"2020","journal-title":"Genes Dis"},{"issue":"8","key":"10.1016\/j.dsx.2024.102949_bib74","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00415-019-09366-1","article-title":"A randomized controlled trial on the efficacy, safety, and pharmacokinetics of metformin in severe traumatic brain injury","volume":"266","author":"Taheri","year":"2019","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13195-020-00589-3","article-title":"Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury","volume":"12","author":"Li","year":"2020","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib76","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/neu.2019.6538","article-title":"Magnetic resonance imaging pilot study of intravenous glyburide in traumatic brain injury","volume":"37","author":"Eisenberg","year":"2020","journal-title":"J Neurotrauma"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib77","doi-asserted-by":"crossref","DOI":"10.5812\/traumamon.25113","article-title":"Evaluation of the effect of glibenclamide in patients with diffuse axonal injury due to moderate to severe head trauma","volume":"21","author":"Zafardoost","year":"2016","journal-title":"Trauma Mon"},{"issue":"10","key":"10.1016\/j.dsx.2024.102949_bib78","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.clineuro.2013.08.010","article-title":"Influence of glibenclamide on outcome in patients with type 2 diabetes and traumatic brain injury","volume":"115","author":"Ding","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.dsx.2024.102949_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104611","article-title":"Pioglitazone improves working memory performance when administered in chronic TBI","volume":"132","author":"McGuire","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.dsx.2024.102949_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114100","article-title":"Peroxisome proliferator-activated receptor-\u03b3 ameliorates neuronal ferroptosis after traumatic brain injury in mice by inhibiting cyclooxygenase-2","volume":"354","author":"Liang","year":"2022","journal-title":"Exp Neurol"},{"key":"10.1016\/j.dsx.2024.102949_bib81","first-page":"1","article-title":"The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone","author":"Yi","year":"2019","journal-title":"J Neurosurg"},{"key":"10.1016\/j.dsx.2024.102949_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113243","article-title":"Bioenergetic restoration and neuroprotection after therapeutic targeting of mitoNEET: new mechanism of pioglitazone following traumatic brain injury","volume":"327","author":"Yonutas","year":"2020","journal-title":"Exp Neurol"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.expneurol.2010.10.003","article-title":"Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury","volume":"227","author":"Sauerbeck","year":"2011","journal-title":"Exp Neurol"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib84","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1089\/neu.2010.1685","article-title":"Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-\u03b3-independent mechanisms","volume":"28","author":"Thal","year":"2011","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib85","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/neu.2015.4361","article-title":"Pioglitazone attenuates neuroinflammation and promotes dopaminergic neuronal survival in the nigrostriatal system of rats after diffuse brain injury","volume":"34","author":"Liu","year":"2017","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.dsx.2024.102949_bib86","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pnpbp.2015.01.003","article-title":"A single dose of PPAR\u03b3 agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats","volume":"59","author":"Pilipovi\u0107","year":"2015","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.dsx.2024.102949_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49428-y","article-title":"Pioglitazone treatment prior to transplantation improves the efficacy of human mesenchymal stem cells after traumatic brain injury in rats","volume":"9","author":"Das","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib88","first-page":"182","article-title":"[Pioglitazone decreases the levels of inflammatory cytokines in SD rats with traumatic brain injury via up-regulating PPAR\u03b3]","volume":"32","author":"Qiu","year":"2016","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.dsx.2024.102949_bib92","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.brainres.2008.09.074","article-title":"PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms","volume":"1244","author":"Yi","year":"2008","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib93","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1096\/fj.201902818R","article-title":"DPP-4 inhibitor reduces striatal microglial deramification after sensorimotor cortex injury induced by external force impact","volume":"34","author":"Hung","year":"2020","journal-title":"Faseb J : official publication of the Federation of American Societies for Experimental Biology"},{"key":"10.1016\/j.dsx.2024.102949_bib94","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fphar.2016.00450","article-title":"Oral administration of sitagliptin activates CREB and is neuroprotective in murine model of brain trauma","volume":"7","author":"DellaValle","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.dsx.2024.102949_bib97","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fcell.2019.00356","article-title":"Neuroprotective effects and treatment potential of incretin mimetics in a murine model of mild traumatic brain injury","volume":"7","author":"Bader","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.dsx.2024.102949_bib102","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.nbd.2018.11.023","article-title":"Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury","volume":"124","author":"Bader","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.dsx.2024.102949_bib103","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neures.2021.05.007","article-title":"Metformin reduces neuroinflammation and improves cognitive functions after traumatic brain injury","volume":"172","author":"DiBona","year":"2021","journal-title":"Neurosci Res"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib104","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jrr\/rrab012","article-title":"Pretreatment with metformin protects mice from whole-body irradiation","volume":"62","author":"Da","year":"2021","journal-title":"J Radiat Res"},{"issue":"7","key":"10.1016\/j.dsx.2024.102949_bib105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s11011-020-00594-3","article-title":"Neuroprotective effects of metformin on traumatic brain injury in rats is associated with the AMP-activated protein kinase signaling pathway","volume":"35","author":"Rahimi","year":"2020","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.dsx.2024.102949_bib106","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainresbull.2018.04.008","article-title":"Neuroprotective effects of metformin on traumatic brain injury in rats associated with NF-\u03baB and MAPK signaling pathway","volume":"140","author":"Tao","year":"2018","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.dsx.2024.102949_bib107","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainresbull.2020.08.021","article-title":"Delayed metformin treatment improves functional recovery following traumatic brain injury via central AMPK-dependent brain tissue repair","volume":"164","author":"Fan","year":"2020","journal-title":"Brain Res Bull"},{"issue":"6","key":"10.1016\/j.dsx.2024.102949_bib98","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/jnc.13169","article-title":"Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice","volume":"135","author":"Li","year":"2015","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.dsx.2024.102949_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120074","article-title":"Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury","volume":"10","author":"Hakon","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10162-022-00862-2","article-title":"Mitigation of hearing damage after repeated blast exposures in animal model of Chinchilla","volume":"23","author":"Jiang","year":"2022","journal-title":"Journal of the Association for Research in Otolaryngology : JARO"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib90","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbrc.2016.03.003","article-title":"Rosiglitazone attenuates inflammation and CA3 neuronal loss following traumatic brain injury in rats","volume":"472","author":"Liu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib91","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.3892\/mmr.2015.4292","article-title":"Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury","volume":"12","author":"Yao","year":"2015","journal-title":"Mol Med Rep"},{"issue":"17","key":"10.1016\/j.dsx.2024.102949_bib114","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1089\/neu.2016.4696","article-title":"Glibenclamide produces region-dependent effects on cerebral edema in a combined injury model of traumatic brain injury and hemorrhagic shock in mice","volume":"35","author":"Jha","year":"2018","journal-title":"J Neurotrauma"},{"issue":"12","key":"10.1016\/j.dsx.2024.102949_bib111","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1089\/neu.2009.1021","article-title":"Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion","volume":"26","author":"Simard","year":"2009","journal-title":"J Neurotrauma"},{"issue":"12","key":"10.1016\/j.dsx.2024.102949_bib109","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/NEN.0b013e3181fbf6d6","article-title":"Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury","volume":"69","author":"Patel","year":"2010","journal-title":"Journal of neuropathology and experimental neurology"},{"issue":"4","key":"10.1016\/j.dsx.2024.102949_bib112","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1089\/neu.2016.4491","article-title":"Glibenclamide attenuates blood-brain barrier disruption in adult mice after traumatic brain injury","volume":"34","author":"Xu","year":"2017","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1016\/j.dsx.2024.102949_bib115","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/CCM.0000000000005749","article-title":"Precision effects of glibenclamide on MRI endophenotypes in clinically relevant murine traumatic brain injury","volume":"51","author":"Zusman","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1016\/j.dsx.2024.102949_bib110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbr.2017.06.038","article-title":"Glibenclamide pretreatment protects against chronic memory dysfunction and glial activation in rat cranial blast traumatic brain injury","volume":"333","author":"Stokum","year":"2017","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.dsx.2024.102949_bib113","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2014.04.040","article-title":"Glibenclamide reduces secondary brain damage after experimental traumatic brain injury","volume":"272","author":"Zweckberger","year":"2014","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.dsx.2024.102949_bib108","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/neu.2020.7421","article-title":"Glibenclamide treatment in traumatic brain injury: operation brain trauma therapy","volume":"38","author":"Jha","year":"2021","journal-title":"J Neurotrauma"},{"issue":"19","key":"10.1016\/j.dsx.2024.102949_bib89","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1089\/neu.2017.5540","article-title":"Polarization of microglia to the M2 phenotype in a peroxisome proliferator-activated receptor gamma-dependent manner attenuates axonal injury induced by traumatic brain injury in mice","volume":"35","author":"Wen","year":"2018","journal-title":"J Neurotrauma"},{"key":"10.1016\/j.dsx.2024.102949_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.dsx.2024.102949_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118645","article-title":"GLP-1 mimetics and cognition","volume":"264","author":"Yaribeygi","year":"2021","journal-title":"Life Sci"},{"issue":"1 Suppl","key":"10.1016\/j.dsx.2024.102949_bib101","first-page":"S62","article-title":"Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury","volume":"10","author":"Greig","year":"2014","journal-title":"Alzheimer's Dementia : the journal of the Alzheimer's Association."}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124000109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402124000109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T19:19:40Z","timestamp":1724008780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402124000109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":116,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1871402124000109"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2024.102949","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of anti-diabetic drugs on traumatic brain injury","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2024.102949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102949"}}